Lung Cancer Clinical Trial
Official title:
A Phase II Study of Neoadjuvant Therapy With Docetaxel, Carboplatin, and Bevacizumab in Patients With Resectable Early Stage Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of tumor cells by blocking blood flow to the tumor. Giving docetaxel and carboplatin
together with bevacizumab before surgery may make the tumor smaller and reduce the amount of
normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well giving docetaxel and carboplatin together
with bevacizumab works in treating patients with stage I, stage II, or stage III non-small
cell lung cancer that can be removed by surgery.
Status | Terminated |
Enrollment | 1 |
Est. completion date | April 2007 |
Est. primary completion date | March 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed non-small cell lung cancer - No squamous cell carcinoma - No histology in close proximity to a major vessel - Resectable stage IB-IIIA disease - No CNS or brain metastases PATIENT CHARACTERISTICS: - ECOG performance status 0-1 - Absolute neutrophil count = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Hemoglobin = 8.0 g/dL - Bilirubin normal - Creatinine = 1.5 mg/dL - Urine protein:creatinine < 1.0 - Alkaline phosphatase (AP), AST, and ALT must meet 1 of the following criteria: - AP normal AND AST and ALT = 5 times upper limit of normal (ULN) - AP = 2.5 times ULN AND AST and ALT = 1.5 times ULN - AP = 5 times ULN AND AST and ALT normal - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment - Adequate pulmonary and cardiovascular function to tolerate surgical resection - No cavitation or history of hemoptysis (i.e., bright red blood = ½ teaspoon) - No existing peripheral neuropathy = grade 1 - No known history of severe hypersensitivity reaction to drugs formulated with polysorbate 80 - No history of serious systemic disease, including any of the following: - Myocardial infarction within the past 6 months - Uncontrolled hypertension (i.e., blood pressure > 150/110 mm Hg on medication) - Unstable angina - New York Heart Association class II-IV congestive heart failure - Unstable symptomatic arrhythmia requiring medication - Patients with chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) are eligible - Clinically significant peripheral vascular disease (i.e., grade II or higher) - No history of significant neurological or psychiatric condition - No known active infection within the past 14 days - No serious, nonhealing wound, ulcer, or bone fracture - No evidence of bleeding diathesis or coagulopathy - No stroke within the past 6 months - No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days - No other serious illness or medical condition - No active infection - No other currently active malignancy except nonmelanoma skin cancer - Malignancies for which therapy has been completed and are considered to have = 30% chance of risk of relapse are not considered active PRIOR CONCURRENT THERAPY: - No prior chemotherapy or VEGF inhibitor - No prior (i.e., within the past 4 weeks), concurrent, or anticipated participation in another experimental drug study except a Genentech-sponsored bevacizumab cancer study - No major surgical procedure, open biopsy, or significant traumatic injury within the past 28 days - No anticipation for major surgical procedure during study treatment - No fine-needle aspiration or core biopsy within 7 days prior to study entry - No concurrent full-dose anticoagulation - No other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy for this cancer |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | UCSF Comprehensive Cancer Center | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical response rate by CT scan after 3 courses of induction treatment | After 3 cycles of induction treatment | No | |
Secondary | Pathologic response rate after 3 courses of induction treatment | After 3 cycles of induction treatment | No | |
Secondary | Resectability rate after 3 courses of induction treatment | After 3 cycles of induction treatment | No | |
Secondary | Median survival at 2 years after surgery | 2 years after surgery | No | |
Secondary | Safety after 3 courses of induction treatment | After 3 cycles of induction treatment | Yes | |
Secondary | Overall survival at 2 years after surgery | 2 years after surgery | No | |
Secondary | Time to treatment failure within 2 years after surgery | 2 years after surgery | No | |
Secondary | Correlation of serum VEGF levels prior to neoadjuvant therapy with primary and secondary objectives prior to start of induction treatment | Before induction treatment | No | |
Secondary | Correlation of serum VEGF expression in resected tumor with primary and secondary objectives | After surgical removal of tumor | No | |
Secondary | Correlation of VEGF levels measured immediately after resection and after adjuvant bevacizumab therapy with primary and secondary objectives | After resection and after adjuvant bevacizumab | No | |
Secondary | Assay additional downstream VEGF activation pathway markers | At any time during the study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|